EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DPP4 inhibitors as a novel therapeutic strategy in colorectal cancer: Integrating network biology and experimental insights

Sanaa K Bardaweel iD, Baraa Abu Sneineh, Rima Hajjo, Reema Abu Khalaf

PLOS One · 2025

DOI: 10.1371/journal.pone.0334223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Sanaa K Bardaweel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Dipeptidyl-Peptidase IV Inhibitors, Dipeptidyl Peptidase 4, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research, University of Jordan, Deanship of Scientific Research, AlZaytoonah University of Jordan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) ranks as the third most prevalent cancer worldwide and the second leading cause of cancer-related deaths. Despite advances in treatment, drug resistance remains a critical challenge. Dipeptidyl peptidase 4 (DPP4), a multifunctional cell surface protein, shows variable expression across malignancies and plays a role in cancer biology. DPP4 inhibitors, initially developed as antidiabetic agents, have demonstrated anticancer properties in several cancer types. In this study, network pharmacology analysis revealed that DPP4 inhibitors modulate critical cancer-associated pathways, such as proteoglycans in cancer, ECM(extracellular matrix)-receptor interaction, and PI3K-AKT (phosphatidylinositol 3-kinase–protein kinase B) signaling. Experimental data showed dose-dependent growth inhibition in four CRC cell lines treated with FDA (Food and Drug Administration)-approved and novel DPP4 inhibitors. Combination treatments with doxorubicin yielded synergistic effects, whereas those with 5-fluorouracil (5FU) were either synergistic or additive. The examined DPP4 inhibitors effectively suppressed colony formation in HCT-116 cells and induced apoptosis. Additionally, the inhibitors resulted in G0/G1 cell cycle arrest and significantly reduced the expression of CD26 (Cluster of Differentiation 26) , Bcl-2(B-cell lymphoma 2) , and VEGF (Vascular Endothelial Growth Factor) in HCT-116 cells. Our findings highlight the potential therapeutic utility of DPP4 inhibitors in CRC treatment, either as standalone agents or in combination with standard chemotherapeutics. Moreover, the computational insights provided herein enhance our understanding of the molecular mechanisms underlying the anticancer effects of DPP4 inhibitors, paving the way for their potential clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsDipeptidyl-Peptidase IV InhibitorsDipeptidyl Peptidase 4Antineoplastic AgentsHumansApoptosisFluorouracilCell Line, TumorCell ProliferationSignal TransductionDoxorubicinNetwork PharmacologyHCT116 CellsDrug Synergism

Substanzen

Dipeptidyl-Peptidase IV InhibitorsDipeptidyl Peptidase 4FluorouracilDPP4 protein, humanDoxorubicinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman, Jordan.
  • Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
  • Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of Americ…
  • Board Member, Jordan CDC, Amman, Jordan.

ORCID-Profile: Sanaa K Bardaweel

Förderung

  • Deanship of Scientific Research, University of Jordan
  • Deanship of Scientific Research, AlZaytoonah University of Jordan

Zitieren

APA

Bardaweel, S. K., Abu Sneineh, B., Hajjo, R., & Abu Khalaf, R. (2025). DPP4 inhibitors as a novel therapeutic strategy in colorectal cancer: Integrating network biology and experimental insights. PLOS One. https://doi.org/10.1371/journal.pone.0334223

Vancouver

Bardaweel SK, Abu Sneineh B, Hajjo R, Abu Khalaf R. DPP4 inhibitors as a novel therapeutic strategy in colorectal cancer: Integrating network biology and experimental insights. PLOS One. 2025. doi:10.1371/journal.pone.0334223

BibTeX
@article{Bardaweel2025,
  author = {Bardaweel, Sanaa K and Abu Sneineh, Baraa and Hajjo, Rima and Abu Khalaf, Reema},
  title = {DPP4 inhibitors as a novel therapeutic strategy in colorectal cancer: Integrating network biology and experimental insights},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0334223}
}
Kostenlos starten →